アムジェン株式会社（本社：東京、代表取締役社長：スザナ・ムルテイラ、以下「アムジェン」）は、循環器病対策の取り組みの一つとして、一般社団法人日本循環器協会（以下「日本循環器協会」）と共に急性冠症候群（ACS）再発予防のためのACSヘルスケアエコシステム形成プロジェクトを推進しています。その一環として、アムジェンと日本循環器協会は、全国のACSの地域連携クリニカルパスの普及率と使用状況を明らかにするため、全国の日本循環器協会支部に対しウェブベースの調査を実施しました。
この調査の結果、全国で18の地域においてACS地域連携クリニカルパスの存在が明らかとなり、このうち11都道府県（23％）が都道府県全体でクリニカルパスを活用し、さらに4県（9％）が地域単位で活用している実態が示されました。一方で、大多数のACS地域連携クリニカルパスでは低比重リポ蛋白コレステロール（LDL-C）、HbA1c、血圧などのリスク因子の管理目標値が示されているものの、日本の現行ガイドラインでACS患者におけるLCL-C管理目標値とされている70 mg/dL 未満に対応しているパスは 8つにとどまっていることが明らかとなりました。
このように、日本におけるACS地域連携クリニカルパスは都道府県ごとに実施状況が異なっており、今後、ACS患者さんのアウトカムを改善するための包括的で標準化されたクリニカルパスを全国的に確立していく必要性が示されました。
調査概要／結果目的: 全国のACS地域連携クリニカルパスの普及率と使用状況を調査する目的で日本循環器協会（47支部）によるウェブベースの調査を実施（回収率100％）。
調査結果と課題: 全国18の地域でACSクリニカルパスの存在を特定できたが、LDL-Cの目標値を＜70 mg/dL未満に設定しているケースは８つにとどまった。
今後の展望: ACS管理の最適化と全国的な患者転帰の改善に向け、包括的で持続可能かつ標準化されたクリニカルパスの確立が重要である。
なお、一般社団法人日本循環器協会からのリリースはこちらをご覧ください。
急性冠動脈症候群（ACS）について
急性冠症候群 （ACS：Acute Coronary
Syndrome）とは、冠動脈の血管が狭くなったり、詰まったりすることにより、心筋組織に十分な血液が供給されなくなることで引き起こされる症候群のことです。急性心筋梗塞、不安定狭心症、虚血による心臓突然死が含まれます。
一般社団法人日本循環器協会について
一般社団法人日本循環器協会は循環器病対策基本法の施行をうけて、患者・企業・医療者をつなぐ架け橋となるプラットフォームの役割を果たすために2021年に設立された新しい団体です。日本循環器学会、日本心臓財団と緊密に連携をとりながら”もっと近くで”活動しています。詳細は以下のホームページなどからご覧ください。
ホームページ：https://j-circ-assoc.or.jp/
Facebook：https://www.facebook.com/J.Circ.Assoc
Twitter：https://twitter.com/J_Circ_Assoc
アムジェン株式会社について
アムジェン株式会社は、世界最大規模の独立バイオテクノロジー企業である米国アムジェン社の日本法人です。アムジェン株式会社では、循環器疾患、がん、骨疾患、炎症・免疫性疾患、神経疾患、希少疾患を始めとするアンメット・メディカル・ニーズが高い領域に焦点を絞り、「To
serve patients –
患者さんのために、今できるすべてを」というミッションのもと、臨床開発から販売までの活動を行っています。詳細については
www.amgen.co.jp
をご覧になるか、https://www.facebook.com/amgenjapan
をフォローしてください。
Amgen Forward-Looking Statements
This news release contains forward-looking statements that are based on
the current expectations and beliefs of Amgen. All statements, other
than statements of historical fact, are statements that could be deemed
forward-looking statements, including any statements on the outcome,
benefits and synergies of collaborations, or potential collaborations,
with any other company (including BeiGene, Ltd. or Kyowa Kirin Co.,
Ltd.), the performance of Otezla® (apremilast) (including anticipated
Otezla sales growth and the timing of non-GAAP EPS accretion), our
acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon
Therapeutics plc (including the prospective performance and outlook of
Horizon's business, performance and opportunities, any potential
strategic benefits, synergies or opportunities expected as a result of
such acquisition, and any projected impacts from the Horizon acquisition
on our acquisition-related expenses going forward), as well as estimates
of revenues, operating margins, capital expenditures, cash, other
financial metrics, expected legal, arbitration, political, regulatory or
clinical results or practices, customer and prescriber patterns or
practices, reimbursement activities and outcomes, effects of pandemics
or other widespread health problems on our business, outcomes, progress,
and other such estimates and results. Forward-looking statements involve
significant risks and uncertainties, including those discussed below and
more fully described in the Securities and Exchange Commission reports
filed by Amgen, including our most recent annual report on Form 10-K and
any subsequent periodic reports on Form 10-Q and current reports on Form
8-K. Unless otherwise noted, Amgen is providing this information as of
the date of this news release and does not undertake any obligation to
update any forward-looking statements contained in this document as a
result of new information, future events or otherwise.
No forward-looking statement can be guaranteed and actual results may
differ materially from those we project. Our results may be affected by
our ability to successfully market both new and existing products
domestically and internationally, clinical and regulatory developments
involving current and future products, sales growth of recently launched
products, competition from other products including biosimilars,
difficulties or delays in manufacturing our products and global economic
conditions. In addition, sales of our products are affected by pricing
pressure, political and public scrutiny and reimbursement policies
imposed by third-party payers, including governments, private insurance
plans and managed care providers and may be affected by regulatory,
clinical and guideline developments and domestic and international
trends toward managed care and healthcare cost containment. Furthermore,
our research, testing, pricing, marketing and other operations are
subject to extensive regulation by domestic and foreign government
regulatory authorities. We or others could identify safety, side effects
or manufacturing problems with our products, including our devices,
after they are on the market. Our business may be impacted by government
investigations, litigation and product liability claims. In addition,
our business may be impacted by the adoption of new tax legislation or
exposure to additional tax liabilities. If we fail to meet the
compliance obligations in the corporate integrity agreement between us
and the U.S. government, we could become subject to significant
sanctions. Further, while we routinely obtain patents for our products
and technology, the protection offered by our patents and patent
applications may be challenged, invalidated or circumvented by our
competitors, or we may fail to prevail in present and future
intellectual property litigation. We perform a substantial amount of our
commercial manufacturing activities at a few key facilities, including
in Puerto Rico, and also depend on third parties for a portion of our
manufacturing activities, and limits on supply may constrain sales of
certain of our current products and product candidate development. An
outbreak of disease or similar public health threat, such as COVID-19,
and the public and governmental effort to mitigate against the spread of
such disease, could have a significant adverse effect on the supply of
materials for our manufacturing activities, the distribution of our
products, the commercialization of our product candidates, and our
clinical trial operations, and any such events may have a material
adverse effect on our product development, product sales, business and
results of operations. We rely on collaborations with third parties for
the development of some of our product candidates and for the
commercialization and sales of some of our commercial products. In
addition, we compete with other companies with respect to many of our
marketed products as well as for the discovery and development of new
products. Discovery or identification of new product candidates or
development of new indications for existing products cannot be
guaranteed and movement from concept to product is uncertain;
consequently, there can be no guarantee that any particular product
candidate or development of a new indication for an existing product
will be successful and become a commercial product. Further, some raw
materials, medical devices and component parts for our products are
supplied by sole third-party suppliers. Certain of our distributors,
customers and payers have substantial purchasing leverage in their
dealings with us. The discovery of significant problems with a product
similar to one of our products that implicate an entire class of
products could have a material adverse effect on sales of the affected
products and on our business and results of operations. Our efforts to
collaborate with or acquire other companies, products or technology, and
to integrate the operations of companies or to support the products or
technology we have acquired, may not be successful. There can be no
guarantee that we will be able to realize any of the strategic benefits,
synergies or opportunities arising from the Horizon acquisition, and
such benefits, synergies or opportunities may take longer to realize
than expected. We may not be able to successfully integrate Horizon, and
such integration may take longer, be more difficult or cost more than
expected. A breakdown, cyberattack or information security breach of our
information technology systems could compromise the confidentiality,
integrity and availability of our systems and our data. Our stock price
is volatile and may be affected by a number of events. Our business and
operations may be negatively affected by the failure, or perceived
failure, of achieving our environmental, social and governance
objectives. The effects of global climate change and related natural
disasters could negatively affect our business and operations. Global
economic conditions may magnify certain risks that affect our business.
Our business performance could affect or limit the ability of our Board
of Directors to declare a dividend or our ability to pay a dividend or
repurchase our common stock. We may not be able to access the capital
and credit markets on terms that are favorable to us, or at all.
注意事項（アムジェン株式会社）
このニュースリリースに含まれている医薬品（開発中のものを含む）に関する情報は、宣伝広告、医学的アドバイスを目的とするものではありません。
###
この件に関するお問い合わせ先
アムジェン株式会社（東京）
コーポレート・アフェアーズ
jpto-mediarelationsgroup@amgen.com